Selective Cyclo-Oxygenase-2 Inhibitors and Myocardial Infarction: How Strong is the Link?
- Published in:
- Drug Safety, 2002, v. 25, n. 12, p. 829, doi. 10.2165/00002018-200225120-00001
- By:
- Publication type:
- Article
Works matching IS 01145916 AND DT 2002 AND VI 25 AND IP 12
Results: 6
1
2
Hydroxyethylstarch as a risk factor for acute renal failure: is a change of clinical practice indicated?
- Published in:
- 2002
- By:
- Publication type:
- journal article
3
A benefit-risk assessment of class III antiarrhythmic agents.
- Published in:
- 2002
- By:
- Publication type:
- journal article
4
A benefit-risk assessment of extended-release oxybutynin.
- Published in:
- 2002
- By:
- Publication type:
- journal article
5
Oxidation injury in patients receiving HMG-CoA reductase inhibitors: occurrence in patients without enzyme elevation or myopathy.
- Published in:
- 2002
- By:
- Publication type:
- journal article
6
Risk management strategies in the Physicians' Desk Reference product labels for pregnancy category X drugs.
- Published in:
- 2002
- By:
- Publication type:
- journal article